From: Cardiovascular organ damage in type 2 diabetes mellitus: the role of lipids and inflammation
 | T2DM patients | nonT2DM subjects |  |
---|---|---|---|
Gender (M:F) | 148:43 | 66:28 | 0.20 |
Age (years) | 65 ± 7 | 62 ± 8 | < 0.0001 |
T2DM duration (years) | 6 [11] | Â | Â |
Body weight (kg) | 84 ± 15 | 79 ± 12 | < 0.005 |
BMI (kg/m2) | 29.0 ± 4.5 | 27.2 ± 3.6 | < 0.001 |
Waist circumference (cm) | 106 ± 12 | 98 ± 11 | < 0.0001 |
Systolic BP/diastolic BP (mmHg) | 135 ± 19/77 ± 10 | 128 ± 15/78 ± 10 | < 0.05a |
Heart rate (bpm) | 66 ± 11 | 60 ± 9 | < 0.0001 |
LDL-cholesterol (mmol/L) | 2.67 ± 0.85 | 2.86 ± 0.94 | 0.09 |
HDL-cholesterol (mmol/L) | 1.27 ± 0.28 | 1.35 ± 0.35 | < 0.05 |
Triglycerides (mmol/L) | 1.32 [0.82] | 1.25 [0.61] | 0.08 |
Fasting glucose (mmol/L) | 7.4 ± 1.8 | 4.9 ± 0.6 | < 0.0001 |
HbA1c (%) | 7.0 [1.4] | 5.7 [0.4] | < 0.0001 |
hsCRP (mg/dL) | 0.15 [0.26] | 0.17 [0.19] | 0.40 |
IL-6 (AU) | 36 [25] | 29 [25] | < 0.01 |
IL-18 (AU) | 1314 [637] | 1140 [557] | 0.005 |
MMP-12 (AU) | 139 [96] | 98 [58] | < 0.0001 |
BP-lowering therapy (%) | 73.3 | 52.1 | < 0.0005 |
Lipid-lowering therapy (%) | 62.8 | 50.0 | < 0.05 |
Current smoking (%) | 31.1 | 34.0 | 0.57 |
CV events (%) | 49.2 | 40.4 | 0.44a |
cIMT (μm) | 782 ± 129 | 668 ± 139 | < 0.01a |
cIMT > 90th percentile (%) | 33.5 | 18.1 | 0.005 |
IADiam (mm) | 8.52 ± 0.91 | 8.05 ± 0.92 | < 0.005a |
ccaWS (m/s) | 8.9 ± 1.8 | 7.9 ± 1.5 | 0.001a |
cfPWV (m/s) | 11.4 ± 2.4 | 9.3 ± 2.0 | < 0.0001a |
cfPWV > 90th percentile (%) | 27.2 | 4.3 | < 0.0001 |
LV mass (g) | 225 ± 54 | 199 ± 52 | < 0.0005 |
LV hypertrophy (%) | 51.8 | 29.8 | < 0.001 |
s′ velocity (cm/s) | 8.6 ± 1.3 | 8.8 ± 1.6 | 0.28 |
e′ velocity (cm/s) | 8.7 ± 1.4 | 9.7 ± 2.0 | < 0.0005a |
Stroke volume (mL) | 81 ± 16 | 70 ± 19 | < 0.0001 |
End-systolic wall stress (*103 dynes/cm2) | 72 ± 24 | 69 ± 29 | 0.44 |